Literature DB >> 8710040

Uveitis during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and ethambutol.

S H Lowe1, F P Kroon, J G Bollemeyer, B H Stricker, J W van 't Wout.   

Abstract

Three patients with a cellular immunodeficiency were treated with rifabutin, clarithromycin and ethambutol for a disseminated infection with Mycobacterium avium-intracellulare complex (MAC). The patients developed uveitis, sometimes in combination with a transient rash, arthralgia, arthritis, jaundice and pseudojaundice. It seems likely that these reactions were caused by rifabutin, alone or together with other drugs such as clarithromycin. These adverse reactions probably depend on the dose, metabolism and excretion of the drug. Inhibition of cytochrome P450 seems to be an important mechanism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8710040     DOI: 10.1016/0300-2977(95)00099-2

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  2 in total

1.  Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients.

Authors:  Seni Kouanda; Henri Gautier Ouedraogo; Kadari Cisse; Tegwinde Rebeca Compaoré; Giorgia Sulis; Serge Diagbouga; Alberto Roggi; Grissoum Tarnagda; Paola Villani; Lassana Sangare; Jacques Simporé; Mario Regazzi; Alberto Matteelli
Journal:  BMC Infect Dis       Date:  2020-06-26       Impact factor: 3.090

2.  Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week.

Authors:  Henri Gautier Ouedraogo; Alberto Matteelli; Giorgia Sulis; Tegwinde Rebeca Compaore; Serge Diagbouga; Simon Tiendrebeogo; Alberto Roggi; Kadari Cisse; Pier Francesco Giorgetti; Paola Villani; Lassana Sangare; Jacques Simpore; Mario Regazzi; Seni Kouanda
Journal:  Ann Clin Microbiol Antimicrob       Date:  2020-01-22       Impact factor: 3.944

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.